Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study monitors Real-World impact of secukinumab on painful skin condition

NCT ID NCT07282015

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 142 Canadian adults with moderate-to-severe hidradenitis suppurativa who are prescribed secukinumab as part of their regular care. Researchers will track changes in disease severity over 12 months using a standard scoring system. The goal is to understand how well the treatment works in everyday practice and to monitor safety.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 142 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Canadian patients diagnosed with moderate-to-severe HS and treated with secukinumab as per routine clinical practice

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients must give written, signed, and dated informed consent before any information is collected and any study-related activity is performed. 2. Adult patients at the time of informed consent signature. 3. Patients with the diagnosis of moderate-to-severe HS, as determined by the dermatologist. 4. Patients who have been newly prescribed secukinumab as part of routine clinical care according to the approved Canadian PM. The decision to prescribe secukinumab must be made prior to,and independent of, study participation. First treatment with secukinumab must occur no more than 7 days (≤7 days) prior to Baseline visit. 5. Patients who can understand written and spoken Canadian English or French. Exclusion Criteria: 1. Any medical or psychological condition in the treating physician's opinion that may prevent the patient from study participation. 2. Patients who have any contraindications to treatment with secukinumab, as defined in the Canadian PM. 3. Patients who have had any prior exposure to secukinumab (i.e., \>7 days prior to the baseline visit).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hidradenitis suppurativa

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    15 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Calgary, Alberta, T2J 7E1, Canada

  • Novartis Investigative Site

    RECRUITING

    Calgary, Alberta, T3E 0B2, Canada

  • Novartis Investigative Site

    RECRUITING

    Winnipeg, Manitoba, R3M 3Z4, Canada

  • Novartis Investigative Site

    RECRUITING

    Fredericton, New Brunswick, E3B 1G9, Canada

  • Novartis Investigative Site

    RECRUITING

    St. John's, Newfoundland and Labrador, A1E 1V4, Canada

  • Novartis Investigative Site

    RECRUITING

    Cobourg, Ontario, K9A 4J9, Canada

  • Novartis Investigative Site

    RECRUITING

    Hamilton, Ontario, L8P4B4, Canada

  • Novartis Investigative Site

    RECRUITING

    London, Ontario, N6H 5L5, Canada

  • Novartis Investigative Site

    RECRUITING

    Markham, Ontario, L3P 1X3, Canada

  • Novartis Investigative Site

    RECRUITING

    Mississauga, Ontario, L4W 0C2, Canada

  • Novartis Investigative Site

    RECRUITING

    Richmond Hill, Ontario, L4C 9M7, Canada

  • Novartis Investigative Site

    RECRUITING

    Toronto, Ontario, M4E 1R7, Canada

  • Novartis Investigative Site

    RECRUITING

    Saint-Jérôme, Quebec, J7Z 7E2, Canada

  • Novartis Investigative Site

    RECRUITING

    Sherbrooke, Quebec, J1L 0H8, Canada

  • Novartis Investigative Site

    RECRUITING

    Saskatoon, Saskatchewan, S7N0N5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.